Parkinson Disease
Conditions
Keywords
coenzyme Q10, Parkinson disease, oxidative damage
Brief summary
The investigators hypothesise that measuring biomarkers of oxidative damage could better inform investigators on the potential merits (and pitfalls) of CoQ10 supplementation in PD subjects.
Detailed description
Subjects with idiopathic PD will be recruited to a 10-week dose escalation study. Each dosage (400mg/day, 800mg/day, 1200/day and 2400mg/day) will be consumed daily for two weeks. Information on safety and fasting blood/urine samples will be collected. Primary endpoint is plasma F2-isoprostanes (adjusted for arachidonate) while secondary endpoint is the change in the total Unified Parkinson Disease Rating Scale (UPDRS) before and after treatment. Serum phospholipase A2 activities, plasma all trans-retinol, plasma total tocopherol (sum of α-, δ- and γ-tocopherol) and serum uric acid will be measured.
Interventions
DIETARY_SUPPLEMENTcoenzyme q10
400mg/day, 800mg/day, 1200/day and 2400mg/day
Sponsors
National University Hospital, Singapore
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Months to No maximum
Healthy volunteers
No
Inclusion criteria
* idiopathic Parkinson disease * age \>21 years * able to provide written informed consent
Exclusion criteria
* diabetes mellitus, stroke, cardiac and renal diseases and cigarette smoking * major psychiatric disorder or drug and/or alcohol abuse/dependence * regular use of antioxidants, dietary supplements, traditional Chinese remedies, non-steroidal anti-inflammatory drugs or immunosuppressive drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Biomarkers of oxidative damage | 10 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Total Unified Parkinson's Disease Rating Scale (UPDRS) | 10 weeks |
Countries
Singapore
Outcome results
None listed